The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of prior treatment (tx) on the clinical activity of imetelstat (IME) in transfusion-dependent (TD) patients (pts) with erythropoiesis-stimulating agent (ESA), relapsed or refractory (R/R)/ineligible lower-risk myelodysplastic syndromes (LR-MDS).
 
Rami Komrokji
Stock and Other Ownership Interests - Abbvie
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; DSI; Genentech; Geron; Janssen; Jazz Pharmaceuticals; Pharmaessentia; Rigel; Servio; SOBI; Sumitomo Pharma Oncology
Speakers' Bureau - Jazz Pharmaceuticals; Pharmaessentia; Rigel; SERVIER; SOBI
Research Funding - Bristol-Myers Squibb/Celgene (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Jazz Pharmaceuticals; Pharmaessentia
 
Valeria Santini
Honoraria - Celgene/Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - Abbvie; Ascentage Pharma; Celgene/Bristol-Myers Squibb; Curis; Geron; Gilead Sciences; GlaxoSmithKline; Keros Therapeutics; Novartis; Otsuka; SERVIER; Syros Pharmaceuticals
Research Funding - Celgene (Inst)
Travel, Accommodations, Expenses - Celgene; Janssen-Cilag; Jazz Pharmaceuticals
 
Amer Zeidan
Honoraria - Abbvie; Agios; Akeso Biopharma; ALX Oncology; Amgen; Astellas Pharma; BeiGene; BioCryst; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Daiichi Sankyo; Epizyme; Faron Pharmaceuticals; Genentech; Geron; Gilead Sciences; Glycomimetics; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Keros Therapeutics; Kura Oncology; Kyowa Kirin International; lava therapeutics; Mendus; Notable Labs; Novartis; Orum Therapeutics; Otsuka; Pfizer; Regeneron; Rigel; Schrodinger; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda; Treadwell Therapeutics; Vincerx Pharma; Zentalis
Consulting or Advisory Role - Abbvie; Agios; Akeso Biopharma; ALX Oncology; Amgen; Astellas Pharma; Astex Pharmaceuticals; BeiGene; BioCryst; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Daiichi Sankyo; Epizyme; Faron Pharmaceuticals; Genentech; Geron; Gilead Sciences; Glycomimetics; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Keros Therapeutics; Kura Oncology; Kyowa Kirin International; lava therapeutics; Mendus; Notable Labs; Novartis; Orum Therapeutics; Otsuka; Pfizer; Regeneron; Rigel; Schrodinger; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda; Treadwell Therapeutics; Vincerx Pharma; Zentalis
Research Funding - Abbvie (Inst); Amgen; Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Geron; Kura Oncology; Novartis (Inst); Otsuka; Shattuck Labs; Syros Pharmaceuticals; Takeda (Inst)
 
Mikkael Sekeres
Consulting or Advisory Role - Agios; AstraZeneca; Bristol-Myers Squibb/Celgene; Kurome Therapeutics; Syros Pharmaceuticals
Research Funding - Bristol-Myers Squibb (Inst); Rigel (Inst); Takeda (Inst)
 
Pierre Fenaux
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
 
Azra Raza
Leadership - GRAIL; TFC Therapeutics
Stock and Other Ownership Interests - TFC Therapeutics
Honoraria - Epizyme; Taiho Oncology
Consulting or Advisory Role - Genzyme; Janssen; Takeda; TFC Therapeutics
Research Funding - GRAIL; Immuneel Therapeutics; Rarecells; Regeneron
Patents, Royalties, Other Intellectual Property - Alercell; TFC Therapeutics
Travel, Accommodations, Expenses - GRAIL; Rarecells
 
Moshe Mittelman
Employment - CanaLean , a start-up, developing an anti-lipid agent
Stock and Other Ownership Interests - CannaLean
Consulting or Advisory Role - Dr. Reddy's Laboratories; Rafa Pharmaceutical
Speakers' Bureau - Novartis
Research Funding - Abbvie (Inst); BMS (Inst); Novartis (Inst)
 
Sylvain Thepot
Honoraria - Abbvie; Astellas Pharma; BMSi; Novartis
Travel, Accommodations, Expenses - Abbvie; Amgen
 
Rena Buckstein
Honoraria - BMSi; Taiho Oncology
Consulting or Advisory Role - BMSi; Keros Therapeutics; MDS Foundation
Research Funding - BMSi (Inst); Taiho Pharmaceutical (Inst)
(OPTIONAL) Uncompensated Relationships - BMSi
 
Ulrich Germing
Honoraria - Celgene; Jazz Pharmaceuticals; Novartis
Consulting or Advisory Role - Celgene
Research Funding - Celgene (Inst); Novartis (Inst); Novartis (Inst)
 
Yazan Madanat
Honoraria - Blueprint Medicines; Bristol Myers Squibb; GERON; Kura Oncology; MorphoSys; Novartis; OncLive/MJH Life Sciences; Rigel; Sierra Oncology; SOBI; Stemline Therapeutics; Taiho Oncology
Consulting or Advisory Role - Geron
Travel, Accommodations, Expenses - Blueprint Medicines; MorphoSys
 
Maria Diez-Campelo
Honoraria - Abbvie; Bristol-Myers Squibb/Celgene; Keros Therapeutics; Novartis
Consulting or Advisory Role - AGIOS; Ascentage Pharma; Bristol-Myers Squibb/Celgene; Curis; GlaxoSmithKline; HEMAVAN; Keros Therapeutics; Otsuka; Syros Pharmaceuticals
Travel, Accommodations, Expenses - Gilead Sciences; Novartis
 
David Valcárcel
Consulting or Advisory Role - Amgen; BMS; Celgene; GlaxoSmithKline; Jazz Pharmaceuticals; NOVARTIS; Pfizer; Sanofi; SOBI; Takeda
Speakers' Bureau - Amgen; Astellas Pharma; Astellas Pharma; BMS; Celgene; Gebro Pharma; GlaxoSmithKline; Jazz Pharmaceuticals; Kite, a Gilead company; Novartis; Pfizer; Sanofi/Aventis; SOBI
Travel, Accommodations, Expenses - Amgen; Celgene; GlaxoSmithKline; Jazz Pharmaceuticals; Pfizer
 
Anna Jonasova
No Relationships to Disclose
 
Sheetal Shah
Employment - Geron
Stock and Other Ownership Interests - Geron
 
Qi Xia
Employment - Geron
Stock and Other Ownership Interests - Geron
 
Libo Sun
Employment - Geron
Stock and Other Ownership Interests - Geron
 
Shyamala Navada
Employment - Geron
Stock and Other Ownership Interests - Geron
 
Michael Savona
Stock and Other Ownership Interests - Empath Biosciencies; Karyopharm Therapeutics; Ryvu Therapeutics
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; CTI BioPharma Corp; Geron; Karyopharm Therapeutics; Novartis; Ryvu Therapeutics; Sierra Oncology
Research Funding - ALX Oncology; Astex Pharmaceuticals; Incyte; Takeda Israel
Travel, Accommodations, Expenses - Astex Pharmaceuticals
 
Uwe Platzbecker
Honoraria - Abbvie; Geron
Research Funding - Abbvie; Geron